MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$3,321K
Free Cash flow
-$18,630K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Maturities of marketable securit...
Proceeds from exercise of stock ...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Prepaid expenses, other current ...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-32,485
-23,627
-29,667
-74,027
Depreciation
7
14
46
217
Stock-based compensation
13,915
7,397
12,311
21,708
Noncash lease expense
126
93
92
261
Amortization of premiums and discounts on marketable securities, net
-511
-266
-55
282
Change in fair value of contingent value right liability
-
-
0
0
Loss on disposal of property and equipment
-
-
-106
-
Prepaid expenses, other current and long-term assets
2,160
-1,647
694
411
Operating lease liabilities
-129
-97
-91
-246
Accounts payable
-1,502
-519
828
-11
Accrued expenses and other liabilities
3,186
-4,465
1,176
-1,672
Net cash used in operating activities
-18,531
-19,291
-15,838
-54,463
Maturities of marketable securities
118,693
108,363
87,689
185,209
Purchases of marketable securities
560,160
65,837
75,523
371,271
Receipt of contingent value right milestone
-
-
0
0
Payment of contingent value right milestone, net of permitted deductions
-
-
0
0
Purchases of property and equipment
99
0
0
158
Proceeds from sale of property and equipment
-
-
213
-
Net cash used in investing activities
-441,566
42,526
12,379
-186,220
Proceeds from exercise of stock options
29,587
10,053
528
1,767
Proceeds from issuance of common stock under the espp
354
-
193
427
Proceeds from issuance of common stock and pre-funded warrants in the public offering, net of issuance costs
-
-
0
216,169
Proceeds from issuance of common stock and pre-funded warrants in the private placement, net of issuance costs
-
-
0
0
Proceeds from issuance of common stock under the sales agreement, net of issuance costs
-
-
0
-
Payment of deferred offering costs
-
-
98
119
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs
433,477
-
-
-
Net cash provided by financing activities
463,418
10,053
623
218,244
Net increase (decrease) in cash, cash equivalents and restricted cash
3,321
33,288
-2,836
-22,439
Cash, cash equivalents and restricted cash at the beginning of the period
132,184
98,896
119,437
119,437
Cash, cash equivalents and restricted cash at the end of the period
135,505
132,184
98,896
101,732
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$433,477K
Proceeds from exercise of
stock options
$29,587K
Proceeds from issuance of
common stock under the...
$354K
Net cash provided by
financing activities
$463,418K
Net increase
(decrease) in cash, cash...
$3,321K
Canceled cashflow
$460,097K
Maturities of marketable
securities
$118,693K
Stock-based compensation
$13,915K
Accrued expenses and
other liabilities
$3,186K
Amortization of premiums and
discounts on marketable...
-$511K
Noncash lease expense
$126K
Depreciation
$7K
Net cash used in
investing activities
-$441,566K
Net cash used in
operating activities
-$18,531K
Canceled cashflow
$118,693K
Canceled cashflow
$17,745K
Purchases of marketable
securities
$560,160K
Net loss
-$32,485K
Purchases of property and
equipment
$99K
Prepaid expenses, other
current and long-term...
$2,160K
Accounts payable
-$1,502K
Operating lease
liabilities
-$129K
Buy us a coffee
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)